MCTL THERAPY:
MULTI-TARGET PERSONALISED IMMUNOTHERAPY FOR SOLID TUMOURS

MCTL—Multi-Target Cytotoxic T Lymphocyte therapy is a personalized cellular immunotherapy platform developed by Bohai Biotech in China, designed specifically for advanced solid tumors where standard chemotherapy, targeted therapy, or single-agent immunotherapy has failed. Instead of attacking one tumor marker, MCTL trains the patient's own T cells to simultaneously recognize and destroy multiple distinct tumor-specific targets.

“Single-target therapies allow tumours to evolve around the target and resume growth. MCTL makes this far harder by attacking a personalised cluster of multiple markers simultaneously.”

• Personalised Target Selection

  A blood sample is analysed against Bohai Biotech's proprietary library of 400+ tumour-associated peptide targets across 19 cancer types. The patient's individual tumour marker profile determines which specific target cluster is selected for T cell activation — unique to each patient.

• Dynamic Target Adaptation

  Because tumours can evolve during treatment, MCTL monitors changes in the patient's tumour marker profile across cycles and adjusts the target panel accordingly — maintaining effectiveness against a shifting tumour and directly combating therapy-induced antigen escape.

MCTL therapy involves a multi-step personalised process unfolding over approximately 4–8 weeks. International patients must plan adequate time in China to complete the full workup, T cell activation, and infusion cycles.

1. 1

   Medical Report Review

   Specialist review of pathology, current imaging, and full prior treatment history at the partnering institution in China. CancerFax prepares and submits the case summary for pre-screening.

2. 2

   Blood Sampling and Target Analysis

   A blood sample is drawn and analysed against Bohai Biotech's 400+ peptide target library. The patient's tumour marker profile determines which targets are expressed and eligible for T cell activation.

3. 3

   Personalised Treatment Plan Formulation

   The treating team selects the optimal target cluster based on the blood analysis results and confirms the personalised treatment protocol, including combination agents (e.g., Toripalimab) if indicated.

4. 4

   T Cell Extraction and Activation

   The patient's T cells are collected via blood draw and transferred to the Bohai Biotech laboratory for activation against the selected target cluster. This manufacturing process typically takes several weeks.

5. 5

   Infusion

   Activated MCTL cells are infused intravenously — typically as one or more cycles depending on the treatment protocol. Monitoring for infusion reactions is conducted during and after each infusion.

6. 6

   Response Assessment and Dynamic Adjustment

   Imaging, blood markers, and clinical assessment evaluate tumour response after infusion. If further cycles are planned, the target panel is updated based on the evolving tumour marker profile to address potential antigen escape.

Immune escape — tumour cells shedding or downregulating surface markers that T cells are trained to attack — is the most common reason immunotherapy eventually fails in solid tumours. MCTL is engineered to make escape far harder through simultaneous multi-target activation and dynamic cycle-by-cycle adaptation.

• Why Single-Target Therapies Fail

  PD-1/PD-L1 checkpoint inhibitors and most targeted therapies attack one mechanism. Genetically unstable tumour cells can mutate or downregulate that single target, allowing the cancer to resume growth unchecked. This is antigen loss — the primary driver of acquired immunotherapy resistance in solid tumours.

• How MCTL Addresses This

  By activating T cells against a cluster of multiple tumour-specific targets simultaneously, MCTL creates redundancy: even if a tumour cell loses one marker, activated T cells recognising the remaining targets can still identify and destroy it. Dynamic target adjustment across cycles adds a second layer of resistance against evolving tumour antigen profiles.

Bohai Biotech's MCTL platform covers 19 solid tumour types. The most substantial published clinical data is available for NSCLC, colorectal, pancreatic, liver, and breast cancer — all common cancers where standard immunotherapy has limited efficacy.

The most significant published results for MCTL therapy come from a comparative study in advanced NSCLC — the most common and difficult-to-treat solid tumour — conducted at Peking Union Medical College Hospital, Chinese PLA General Hospital, and Tianjin Medical University Cancer Institute.

“MCTL + Toripalimab produced a median overall survival of 24.1 months vs 11.1 months for Docetaxel — more than doubling survival in patients who had already failed first-line treatment.”

• NSCLC Study: MCTL + Toripalimab vs Docetaxel

  Patients with late-stage NSCLC who had failed first-line treatment were randomised to MCTL + Toripalimab (PD-1 inhibitor) or standard second-line Docetaxel chemotherapy. Median OS: 24.1 months vs 11.1 months. Objective response rate: 33.3% vs approximately 10% for chemotherapy — a clinically meaningful improvement across both survival and tumour response endpoints.

• Additional Tumour Type Findings

  Colorectal cancer: positive outcomes reported in patients who had failed prior lines. Pancreatic cancer: preliminary positive data — significant because pancreatic cancer has historically shown minimal response to immunotherapy. All multi-centre validation studies conducted at three of China's leading oncology research institutions.

• 24.1 moMedian OS (MCTL + Toripalimab)Advanced 2nd-line NSCLC vs 11.1 months for Docetaxel — more than double
• 33.3%Objective Response RateMCTL + Toripalimab in NSCLC vs ~10% for standard second-line chemotherapy
• 400+Peptide Targets in LibraryAcross 19 solid tumour types — the basis for personalised target selection
• 19Solid Tumour Types CoveredIncluding NSCLC, colorectal, pancreatic, liver, breast, gastric cancer, and others
• 8.6Median Progression-Free Survival (MCTL + Toripalimab)In the same phase Ib NSCLC study, median progression-free survival was 8.6 months, adding a useful disease-control benchmark alongside the overall survival number.
• 76.2%Disease Control Rate (MCTL + Toripalimab)Beyond the 33.3% objective response rate, the study reported a 76.2% disease control rate, meaning many additional patients achieved stable disease even if they did not meet formal RECIST response criteria.

MCTL requires individual medical review before eligibility can be confirmed. The following describes the general profile of patients who may be considered based on available clinical data.

The strongest clinical evidence for MCTL comes from combination strategies rather than MCTL as a standalone therapy. Combination flexibility is one of the platform's distinguishing clinical features.

• MCTL + PD-1 Checkpoint Inhibitors

  The landmark NSCLC study used MCTL with Toripalimab (PD-1 inhibitor). The rationale: PD-1 inhibitors release the immunosuppressive brakes tumours use to avoid immune attack, while MCTL provides the specifically targeted, activated T cells to exploit that window. The combination produced 24.1 months median OS vs 11.1 months for chemotherapy alone.

• MCTL + Chemotherapy

  In some protocols, chemotherapy is used to reduce tumour burden before MCTL infusion — creating a more favourable immune environment (reduced immunosuppression, improved antigen presentation) for the activated T cells to operate in.

• MCTL + Targeted Therapy

  For patients with actionable mutations (EGFR in NSCLC, KRAS in colorectal cancer), MCTL may be studied alongside molecularly targeted drugs as a strategy to address residual disease or acquired targeted therapy resistance. Bohai Biotech has also partnered with Jiuzhou Pharmaceutical for complementary peptide drugs and vaccines.

• MCTL vs CAR-T: Key Distinction

  Both use the patient's own T cells, but CAR-T genetically modifies them to carry an artificial receptor targeting a single antigen — highly effective in blood cancers but technically challenging for solid tumours. MCTL does not involve genetic modification, targets multiple antigens simultaneously, has a more manageable safety profile, and is specifically designed for solid tumours.

MCTL is an autologous cellular therapy using the patient's own T cells without genetic modification — generally producing a more manageable safety profile than CAR-T therapy. All immune-based therapies require medical oversight and monitoring.

A structured pre-treatment workup confirms the presence of MCTL-targetable markers, assesses current disease status, and ensures the patient is safe to receive cellular therapy. These documents should be prepared before arrival in China.

Understanding MCTL's current regulatory status clearly is essential for making an informed treatment decision. CancerFax is committed to full transparency on this point.

• Current Regulatory Status

  MCTL therapy is currently in clinical research phases in China and has not yet received full regulatory approval from China's NMPA as a standard therapy. Bohai Biotech has received Class I new drug clinical trial approval for one multi-target anti-tumour cell product. It is not approved by US FDA, European EMA, or equivalent agencies. Access is through regulated clinical trials or compassionate use protocols at authorised partner institutions.

• What This Means for International Patients

  International patients must travel to China and access MCTL through regulated clinical trial protocols or institutional access programmes at authorised centres. CancerFax assists with identifying current enrolment opportunities, assessing eligibility, and coordinating the full practical process — from medical record submission through to arrival, treatment, and post-treatment follow-up.

MCTL therapy cost in China depends on the number of cycles, combination agents used, length of stay, and institutional fees. As an advanced personalised cellular therapy, cost is substantially higher than conventional chemotherapy — but significantly lower than comparable cellular therapies in Western markets.

Explore dedicated short-form pages covering specific MCTL questions, ranging from cancer-type eligibility to accessing trials and traveling to China.

Frequently Asked Questions About MCTL Therapy